

Grifols, S.A. ("**Grifols**"), in accordance with the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, reports the following

OTHER RELEVANT INFORMATION

Grifols has executed a non-binding term sheet with the Public Investment Fund ("**PIF**") of the Kingdom of Saudi Arabia ("**KSA**") whereby, subject to the negotiation and conclusion of definitive binding agreements, both parties shall incorporate a joint venture ("**JV**") in order to develop a plasma collection network, a plasma fractionation facility and a purification plant in the KSA.

According to the non-binding term sheet, the JV will be jointly owned by Grifols and PIF. The financing needs of the project will be determined by the parties depending on the specific needs of each phase of the project.

As part of the recognized value to be contributed by Grifols into the JV, Grifols will provide its knowledge and expertise in the industry as well as intellectual property held by it, providing, among others, engineering services and quality assurance support to set the infrastructure and processes of the JV to the strictest quality and safety standards. Further, whilst the infrastructure is pending to be finalized and fully up and running through contract manufacturing and distribution arrangements, Grifols will guarantee the supply of plasma-derived products to Saudi Arabia.

In Barcelona, on 18 February 2020

Nuria Martín Barnés
Secretary to the Board of Directors